Biofrontera (NASDAQ:BFRI – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Biofrontera to related businesses based on the strength of its analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.
Risk & Volatility
Biofrontera has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Biofrontera’s competitors have a beta of -0.05, meaning that their average share price is 105% less volatile than the S&P 500.
Valuation & Earnings
This table compares Biofrontera and its competitors revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Biofrontera | $41.71 million | -$10.54 million | -2.35 |
| Biofrontera Competitors | $3.56 billion | $3.18 billion | 556.73 |
Biofrontera’s competitors have higher revenue and earnings than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Biofrontera and its competitors, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biofrontera | 1 | 1 | 0 | 0 | 1.50 |
| Biofrontera Competitors | 7859 | 13810 | 25855 | 1041 | 2.41 |
As a group, “Pharmaceuticals” companies have a potential upside of 29.49%. Given Biofrontera’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Biofrontera has less favorable growth aspects than its competitors.
Insider and Institutional Ownership
10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 8.1% of Biofrontera shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Biofrontera and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biofrontera | -12.72% | -131.54% | -29.61% |
| Biofrontera Competitors | -2,391.72% | -204.89% | -14.89% |
Summary
Biofrontera competitors beat Biofrontera on 10 of the 13 factors compared.
About Biofrontera
Biofrontera Inc. is a biopharmaceutical company focused on dermatology and the commercial development of prescription products for treating skin conditions. Its business is primarily centered on the U.S. market. The company’s main product is Ameluz, a topical gel containing aminolevulinic acid hydrochloride. It is used with Biofrontera’s BF-RhodoLED light device in photodynamic therapy to treat certain actinic keratoses, precancerous lesions that can develop on sun-damaged skin. Biofrontera’s products combine a topical treatment with a specialized light source, which activates the treatment during a clinical procedure.
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
